Daniel Spratt
Adjunct Professor of Radiation Oncology
[email protected]

Available to mentor
Daniel Spratt
Adjunct Professor
  • Recent Publications
    • Recent Publications See All Publications
    • Journal Article
      Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377.
      Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Int J Radiat Oncol Biol Phys, 2024 Dec 1; 120 (5): 1461 DOI:10.1016/j.ijrobp.2024.08.044
      PMID: 39320298
    • Journal Article
      Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database.
      Pommier P, Xie W, Ravi P, Carrie C, Dignam JJ, Feng F, Sargos P, Sommer SG, Spratt DE, Tombal B, Van Poppel H, Sweeney C. Radiother Oncol, 2024 Dec; 201: 110532 DOI:10.1016/j.radonc.2024.110532
      PMID: 39278317
    • Journal Article
      The disordered negatively charged C-terminus of the large HECT E3 ubiquitin ligase HERC2 provides structural and thermal stability to the HECT C-lobe.
      Waters KL, Rich KJ, Schwaegerle ND, Yang T, Huo S, Spratt DE. Protein Sci, 2024 Dec; 33 (12): e5229 DOI:10.1002/pro.5229
      PMID: 39565083
    • Journal Article
      Response to simprini and Osazuwa-Peters.
      Mani KA, Wu X, Spratt DE, Wang M, Zaorsky NG. J Natl Cancer Inst, 2024 Nov 14; DOI:10.1093/jnci/djae290
      PMID: 39540808
    • Proceeding / Abstract / Poster
      Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.
      Patel KR, Nguyen PL, Proudfoot JA, Liu Y, Pra AD, Spratt DE, Pollack A, Sandler HM, Efstathiou JA, Lawton C, Simko JP, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Pugh SL, Davicioni E, Tran PT, Feng FY. Eur Urol Oncol, 2024 Nov 13; DOI:10.1016/j.euo.2024.10.017
      PMID: 39542826
    • Journal Article
      Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial.
      Roy S, Sun Y, Chi KN, Ong M, Malone S, Wallis CJD, Kishan AU, Malone J, Swami U, Gebrael G, Brown JR, Jia AY, Morgan SC, Saad F, Chowdhury S, Agarwal N, Spratt DE. J Urol, 2024 Nov; 212 (5): 672 - 681. DOI:10.1097/JU.0000000000004158
      PMID: 39058790
    • Journal Article
      Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial.
      Roy S, Saad F, Sun Y, Malone S, Spratt DE, Kishan AU, Wallis CJD, Jia AY, Mohamad O, Swami U, Ong M, Agarwal N, Chowdhury S, Morgan SC. Eur J Cancer, 2024 Nov; 211: 114197 DOI:10.1016/j.ejca.2024.114197
      PMID: 39243730
    • Journal Article
      Further Randomized Data Confirming Minimal Benefit from the Addition of Hormone Therapy to Postoperative Radiotherapy.
      Spratt DE. Eur Urol, 2024 Nov; 86 (5): 431 - 433. DOI:10.1016/j.eururo.2024.08.024
      PMID: 39232980